基于人群测序的常染色体显性多囊肾与多囊肝患病率估计
研究利用gnomAD(15,496全基因组和123,136外显子)和BRAVO(62,784全基因组)两个大型人群测序数据库,严格定义PKD1、PKD2及ADPLD相关基因的罕见变异,并评估致病性。全基因组数据中高置信致病突变给出终生ADPKD患病率下限为9.3例/10,000测序个体,外显子与全基因组估计相似。ADPLD基因截短突变和潜在囊肿修饰基因突变分别见于20.2和103.9例/10,000测序个体。
要点
- 人群全基因组测序提示ADPKD相关突变患病率高于既往预期。
- ADPLD基因功能丧失突变较预期常见,提示存在未识别病例和不完全外显。
- ADPKD表型修饰基因存在大量罕见变异。
核心结论
- 人群全基因组测序提示ADPKD相关突变患病率高于预期。
- ADPLD基因功能丧失突变较预期常见,提示可能有不完全外显。
研究设计与样本
- 利用gnomAD和BRAVO两个大型人群测序数据库进行变异分析。
- gnomAD包含15,496全基因组和123,136外显子序列,BRAVO包含62,784全基因组序列。
- 采用严格标准定义ADPKD、ADPLD及囊肿修饰基因的罕见变异。
主要发现
- 全基因组测序中高置信致病突变给出终生ADPKD患病率下限为9.3例/10,000测序个体。
- 全基因组与外显子数据估计相似。
- ADPLD基因截短突变见于20.2例/10,000测序个体。
- 潜在囊肿修饰基因突变见于103.9例/10,000测序个体。
临床怎么用
- 临床需注意ADPKD实际患病率可能高于既往估计。
- 对于ADPLD相关基因突变,应考虑不完全外显可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Estimating the prevalence of autosomal dominant polycystic kidney disease (ADPKD) is challenging because of age-dependent penetrance and incomplete clinical ascertainment. Early studies estimated the lifetime risk of ADPKD to be about one per 1000 in the general population, whereas recent epidemiologic studies report a point prevalence of three to five cases per 10,000 in the general population. METHODS: To measure the frequency of high-confidence mutations presumed to be causative in ADPKD and autosomal dominant polycystic liver disease (ADPLD) and estimate lifetime ADPKD prevalence, we used two large, population sequencing databases, gnomAD (15,496 whole-genome sequences; 123,136 exome sequences) and BRAVO (62,784 whole-genome sequences). We used stringent criteria for defining rare variants in genes involved in ADPKD (PKD1, PKD2), ADPLD (PRKCSH, SEC63, GANAB, ALG8, SEC61B, LRP5), and potential cystic disease modifiers; evaluated variants for quality and annotation; compared variants with data from an ADPKD mutation database; and used bioinformatic tools to predict pathogenicity. RESULTS: Identification of high-confidence pathogenic mutations in whole-genome sequencing provided a lower boundary for lifetime ADPKD prevalence of 9.3 cases per 10,000 sequenced. Estimates from whole-genome and exome data were similar. Truncating mutations in ADPLD genes and genes of potential relevance as cyst modifiers were found in 20.2 cases and 103.9 cases per 10,000 sequenced, respectively. CONCLUSIONS: Population whole-genome sequencing suggests a higher than expected prevalence of ADPKD-associated mutations. Loss-of-function mutations in ADPLD genes are also more common than expected, suggesting the possibility of unrecognized cases and incomplete penetrance. Substantial rare variation exists in genes with potential for phenotype modification in ADPKD.
引用
- Lanktree MB, Haghighi A, Guiard E, et al. Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing. J Am Soc Nephrol. 2018. PMID: 30135240. doi:10.1681/ASN.2018050493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。